This gene makes a protein, BCR-ABL, which causes CML cells to grow and reproduce out of control. BCR-ABL is a type of protein known as a tyrosine kinase. Drugs known as tyrosine …

2023年1月16日 · Chronic myelogenous leukemia (CML), BCR-ABL1-positive, is classified as a myeloproliferative neoplasm predominantly composed of proliferating granulocytes and …

2007年10月1日 · Mutations in the kinase domain (KD) of BCR-ABL are the most prevalent mechanism of acquired imatinib resistance in patients with chronic myeloid leukemia (CML). …

Chronic myeloid leukemia (CML) has been regarded as the paradigmatic example of a malignancy defined by a unique molecular event, the BCR-ABL1 oncogene.

The aim of this study was to standardize RT-PCR in monitoring BCR-ABL levels in CML patients treated with tyrosine kinase inhibitors and correlate BCR-ABL levels with cytogenetic …

2005年2月18日 · Clinical and laboratory studies indicate that the fusion protein BCR–ABL is essential for initiation, maintenance and progression of CML, yet the transformation of CML …

2024年2月1日 · The BCR-ABL oncogene stands as a pivotal genetic anomaly with profound implications for the pathogenesis and progression of specific leukemia forms, notably chronic …

Chronic myelogenous leukemia (CML) requires the BCR/ABL tyrosine kinase for disease onset and maintenance. As a result, CML can be successfully treated with tyrosine kinase inhibitors …

It provided the rationale for producing first imatinib and then a series of small molecules designed to inhibit the tyrosine kinase activity of the Bcr-Abl oncoprotein, all of which can induce …

2020年11月9日 · In CML, p190 Bcr-Abl occurs in a minority of patients associating with distinct hematological features and inferior outcomes, yet the pathogenic role of p190 Bcr-Abl and …